Supernus Pharmaceuticals Stock Z Score

SUPN Stock

USD 35.82 0.30 0.83%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Supernus Pharmaceuticals Piotroski F Score and Supernus Pharmaceuticals Valuation analysis.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

At this time, Supernus Pharmaceuticals' Net Invested Capital is very stable compared to the past year. As of the 22nd of November 2024, Capital Stock is likely to grow to about 58.7 K, while Capital Surpluse is likely to drop about 352.1 M. At this time, Supernus Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 22nd of November 2024, Cost Of Revenue is likely to grow to about 88 M, while Interest Expense is likely to drop about 2.3 M.

Supernus Pharmaceuticals Company Z Score Analysis

Supernus Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Supernus Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Supernus Pharmaceuticals is extremely important. It helps to project a fair market value of Supernus Stock properly, considering its historical fundamentals such as Z Score. Since Supernus Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Supernus Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Supernus Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Current Deferred Revenue	Long Term Debt	Short Term Debt	Property Plant Equipment	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.89	0.8	0.85	-0.07	0.92	0.85	0.97	0.99	0.8	0.65	0.71	0.87	0.38	0.81	0.22	0.78	0.84	0.91	0.85	0.49	0.82	0.95	0.6	0.37
Total Stockholder Equity	0.89		0.57	0.97	-0.26	0.98	0.77	0.81	0.87	0.89	0.61	0.49	0.96	0.29	0.94	0.13	0.95	0.93	0.9	0.91	0.3	0.9	0.94	0.51	0.75
Net Debt	0.8	0.57		0.58	0.17	0.62	0.83	0.88	0.82	0.53	0.32	0.68	0.63	0.53	0.48	0.24	0.43	0.54	0.57	0.62	0.52	0.54	0.78	0.39	0.1
Retained Earnings	0.85	0.97	0.58		-0.24	0.94	0.75	0.78	0.83	0.92	0.43	0.45	0.94	0.31	0.96	0.04	0.95	0.89	0.81	0.89	0.21	0.86	0.93	0.44	0.77
Accounts Payable	-0.07	-0.26	0.17	-0.24		-0.27	0.03	0.01	-0.08	-0.15	-0.09	0.24	-0.25	0.22	-0.2	-0.08	-0.28	-0.25	-0.27	-0.12	0.0	-0.27	-0.11	-0.2	-0.35
Net Receivables	0.92	0.98	0.62	0.94	-0.27		0.79	0.86	0.92	0.88	0.66	0.49	0.93	0.35	0.91	0.15	0.93	0.94	0.92	0.89	0.34	0.91	0.94	0.53	0.66
Short Term Investments	0.85	0.77	0.83	0.75	0.03	0.79		0.81	0.89	0.67	0.56	0.43	0.76	0.68	0.65	0.2	0.67	0.71	0.74	0.68	0.37	0.69	0.84	0.26	0.37
Total Liab	0.97	0.81	0.88	0.78	0.01	0.86	0.81		0.97	0.74	0.57	0.77	0.82	0.37	0.73	0.24	0.69	0.77	0.82	0.82	0.55	0.76	0.94	0.64	0.3
Total Current Assets	0.99	0.87	0.82	0.83	-0.08	0.92	0.89	0.97		0.75	0.66	0.66	0.87	0.43	0.76	0.29	0.75	0.84	0.89	0.81	0.53	0.83	0.94	0.6	0.36
Intangible Assets	0.8	0.89	0.53	0.92	-0.15	0.88	0.67	0.74	0.75		0.42	0.4	0.81	0.36	0.97	-0.31	0.96	0.75	0.73	0.9	-0.07	0.7	0.86	0.27	0.69
Common Stock	0.65	0.61	0.32	0.43	-0.09	0.66	0.56	0.57	0.66	0.42		0.39	0.52	0.25	0.46	0.34	0.48	0.6	0.83	0.51	0.44	0.6	0.54	0.41	0.21
Current Deferred Revenue	0.71	0.49	0.68	0.45	0.24	0.49	0.43	0.77	0.66	0.4	0.39		0.52	0.04	0.45	0.36	0.3	0.46	0.54	0.53	0.66	0.46	0.66	0.66	0.04
Long Term Debt	0.87	0.96	0.63	0.94	-0.25	0.93	0.76	0.82	0.87	0.81	0.52	0.52		0.15	0.88	0.23	0.86	0.9	0.86	0.92	0.42	0.88	0.95	0.64	0.7
Short Term Debt	0.38	0.29	0.53	0.31	0.22	0.35	0.68	0.37	0.43	0.36	0.25	0.04	0.15		0.25	-0.11	0.31	0.23	0.23	0.14	-0.09	0.22	0.33	-0.41	0.09
Property Plant Equipment	0.81	0.94	0.48	0.96	-0.2	0.91	0.65	0.73	0.76	0.97	0.46	0.45	0.88	0.25		-0.17	0.97	0.82	0.79	0.91	0.04	0.76	0.88	0.38	0.77
Net Tangible Assets	0.22	0.13	0.24	0.04	-0.08	0.15	0.2	0.24	0.29	-0.31	0.34	0.36	0.23	-0.11	-0.17		-0.16	0.3	0.29	-0.05	0.91	0.36	0.17	0.57	-0.11
Good Will	0.78	0.95	0.43	0.95	-0.28	0.93	0.67	0.69	0.75	0.96	0.48	0.3	0.86	0.31	0.97	-0.16		0.86	0.8	0.89	0.0	0.81	0.85	0.32	0.8
Long Term Debt Total	0.84	0.93	0.54	0.89	-0.25	0.94	0.71	0.77	0.84	0.75	0.6	0.46	0.9	0.23	0.82	0.3	0.86		0.87	0.83	0.44	1.0	0.87	0.58	0.65
Capital Surpluse	0.91	0.9	0.57	0.81	-0.27	0.92	0.74	0.82	0.89	0.73	0.83	0.54	0.86	0.23	0.79	0.29	0.8	0.87		0.83	0.47	0.85	0.86	0.6	0.48
Deferred Long Term Liab	0.85	0.91	0.62	0.89	-0.12	0.89	0.68	0.82	0.81	0.9	0.51	0.53	0.92	0.14	0.91	-0.05	0.89	0.83	0.83		0.23	0.79	0.91	0.54	0.64
Long Term Investments	0.49	0.3	0.52	0.21	0.0	0.34	0.37	0.55	0.53	-0.07	0.44	0.66	0.42	-0.09	0.04	0.91	0.0	0.44	0.47	0.23		0.49	0.43	0.77	-0.1
Short Long Term Debt	0.82	0.9	0.54	0.86	-0.27	0.91	0.69	0.76	0.83	0.7	0.6	0.46	0.88	0.22	0.76	0.36	0.81	1.0	0.85	0.79	0.49		0.84	0.6	0.61
Net Invested Capital	0.95	0.94	0.78	0.93	-0.11	0.94	0.84	0.94	0.94	0.86	0.54	0.66	0.95	0.33	0.88	0.17	0.85	0.87	0.86	0.91	0.43	0.84		0.59	0.59
Net Working Capital	0.6	0.51	0.39	0.44	-0.2	0.53	0.26	0.64	0.6	0.27	0.41	0.66	0.64	-0.41	0.38	0.57	0.32	0.58	0.6	0.54	0.77	0.6	0.59		0.15
Capital Stock	0.37	0.75	0.1	0.77	-0.35	0.66	0.37	0.3	0.36	0.69	0.21	0.04	0.7	0.09	0.77	-0.11	0.8	0.65	0.48	0.64	-0.1	0.61	0.59	0.15

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict Supernus Pharmaceuticals

Based on the company's disclosures, Supernus Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The z score for all United States stocks is 100.0% higher than that of the company.

Supernus Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Supernus Pharmaceuticals from analyzing Supernus Pharmaceuticals' financial statements. These drivers represent accounts that assess Supernus Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Supernus Pharmaceuticals' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	1.2B	1.3B	1.5B	1.9B	1.6B	1.7B
Enterprise Value	1.4B	1.4B	1.8B	2.3B	1.5B	1.6B

Supernus Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Supernus Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Supernus Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Supernus Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Supernus Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Supernus Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Supernus Pharmaceuticals' value.

		Shares
Pacer Advisors, Inc.	2024-06-30	1.3 M
Morgan Stanley - Brokerage Accounts	2024-06-30	1.3 M
Gw&k Investment Management, Llc	2024-09-30	1.2 M
Aristotle Capital Boston, Llc	2024-06-30	1.2 M
American Century Companies Inc	2024-09-30	1 M
Victory Capital Management Inc.	2024-09-30	742.9 K
Charles Schwab Investment Management Inc	2024-09-30	712.4 K
Ashford Capital Management Inc	2024-06-30	711.9 K
Northern Trust Corp	2024-09-30	606.3 K
Blackrock Inc	2024-06-30	10.4 M
Vanguard Group Inc	2024-09-30	6.1 M

Supernus Fundamentals

	Return On Equity	0.0622
	Return On Asset	0.0289
	Profit Margin	0.09 %
	Operating Margin	0.16 %
	Current Valuation	1.63 B
	Shares Outstanding	55.22 M
	Shares Owned By Insiders	5.01 %
	Shares Owned By Institutions	94.99 %
	Number Of Shares Shorted	6.8 M
	Price To Earning	15.25 X
	Price To Book	1.98 X
	Price To Sales	3.03 X
	Revenue	607.52 M
	Gross Profit	580.02 M
	EBITDA	98.26 M
	Net Income	1.32 M
	Cash And Equivalents	360.79 M
	Cash Per Share	6.74 X
	Total Debt	41.53 M
	Debt To Equity	0.53 %
	Current Ratio	0.85 X
	Book Value Per Share	18.24 X
	Cash Flow From Operations	111.08 M
	Short Ratio	24.57 X
	Earnings Per Share	1.07 X
	Price To Earnings To Growth	1.47 X
	Target Price	39.25
	Number Of Employees	652
	Beta	0.87
	Market Capitalization	1.98 B
	Total Asset	1.28 B
	Retained Earnings	482.56 M
	Working Capital	202.92 M
	Current Asset	105.95 M
	Current Liabilities	56.93 M
	Net Asset	1.28 B

About Supernus Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Supernus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Supernus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Supernus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Supernus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Supernus Stock

0.73	TIL	Instil Bio	Pair Corr
0.68	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr
0.66	ME	23Andme Holding	Pair Corr
0.64	INZY	Inozyme Pharma	Pair Corr
0.61	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.

The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:

How To Invest In Supernus

Details

Is Supernus Stock a good investment?

Details

What is Supernus Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Supernus Pharmaceuticals Piotroski F Score and Supernus Pharmaceuticals Valuation analysis.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.99)

Earnings Share

1.07

Revenue Per Share

11.877

Quarterly Revenue Growth

0.142

Return On Assets

0.0289

The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Supernus Pharmaceuticals Stock Z Score

Supernus Pharmaceuticals Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Supernus Z Score Driver Correlations

Supernus Pharmaceuticals Current Valuation Drivers

Supernus Pharmaceuticals ESG Sustainability

Supernus Pharmaceuticals Institutional Holders

Supernus Fundamentals

About Supernus Pharmaceuticals Fundamental Analysis

Pair Trading with Supernus Pharmaceuticals

Moving against Supernus Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY